A multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetes.

Yang, S J; Min, K W; Gupta, S K; Park, J Y; Shivane, V K; Pitale, S U; Agarwal, P K; Sosale, A; Gandhi, P; Dharmalingam, M; Mohan, V; Mahesh, U; Kim, D M; Kim, Y S; Kim, J A; Kim, P K; Baik, S H.
Diabetes Obes Metab; 15(5): 410-6, 2013 May.
Artigo em Inglês | MEDLINE | ID: mdl-23170990